SAB Biotherapeutics, Inc. (SABS)

Last Closing Price: 5.24 (2024-02-20)

Company Description

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $23.90M
Net Income (Most Recent Fiscal Year) $-18.74M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 7.02
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.88
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -664.04%
Net Margin (Trailing 12 Months) -664.68%
Return on Equity (Trailing 12 Months) -120.36%
Return on Assets (Trailing 12 Months) -69.17%
Current Ratio (Most Recent Fiscal Quarter) 0.34
Quick Ratio (Most Recent Fiscal Quarter) 0.34
Debt to Common Equity (Most Recent Fiscal Quarter) 0.23
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $7.22
Earnings per Share (Most Recent Fiscal Quarter) $-1.00
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) --
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 5.23M
Free Float 3.87M
Market Capitalization $28.72M
Average Volume (Last 20 Days) 0.01M
Beta (Past 60 Months) 0.90
Percentage Held By Insiders (Latest Annual Proxy Report) 25.95%
Percentage Held By Institutions (Latest 13F Reports) 7.82%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%